跳至主要内容
临床试验/JPRN-UMIN000004893
JPRN-UMIN000004893已完成未知

Combination therapy of tacrolimus and intravenous cyclophosphamide for remission induction of lupus nephritis - Combination therapy of tacrolimus and intravenous cyclophosphamide for remission induction of lupus nephritis

Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University0 个研究点目标入组 16 人开始时间: 2011年1月18日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18years-old 至 65years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients are excluded if they meet any one of the following criteria. 1)Patients whose serum creatinine is 2 mg/dL or more; or creatinine clearance is 30 mL/min/1.73m2 or less. 2)Patients needing steroid pulse therapy. 3)Patients having received intravenous cyclophosphamide or steroid pulse therapy within 6 months of the start of the study. 4)Patients having suffered from hypersensitivity against the ingredients of tacrolimus capsules. 5)Patients administered with cyclosporine or bosentan. 6)Patients administered with potassium sparing diuretics. 7)Patients pregnant or suspected to be pregnant; or breast-feeding; or expecting to be pregnant during the study period. 8)Patients administered with pentostatin. 9)Patients having suffered from hypersensitivity against the ingredients of injectable cyclophosphamide. 10)Patients having a serious infectious disease. 11)Patients considered ineligible by a doctor in charge for other reason.

研究者

发起方
Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University

相似试验

Combination therapy of tacrolimus and intravenous... | 临床试验